Fosmanogepix is a Small Molecule owned by Pfizer, and is involved in 13 clinical trials, of which 10 were completed, 2 are ongoing, and 1 is planned.

APX-001 acts as a GWT1 inhibitor. Gwt1, a critical acyltransferase required for the biosynthesis of fungal GPI anchor. APX-001 selectively inhibits inositol acylation of fungus-specific glycosylphosphatidylinositol (GPI) which would be catalyzed by Gwt1 protein. It leads to the inhibition of GPI-anchored protein maturation. APX-001 also suppresses the expression of some important virulence factors of C. albicans, through its GPI biosynthesis inhibition.

The revenue for Fosmanogepix is expected to reach a total of $439m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fosmanogepix NPV Report.

Fosmanogepix was originated by Eisai and is currently owned by Pfizer.

Fosmanogepix Overview

APX-001 is under development for the treatment of drug-resistant candidiasis, invasive aspergillosis, cryptococcosis, coccidioidomycosis, scedosporiosis, fusariosis, mucormycosis and rare moulds. The drug candidate is administered through the intravenous and oral route. The drug candidate targets GWT1 and is developed based on a platform approach to improving small molecule drugs by the addition of a second small molecule to an existing drug.

It was under development for the treatment of candidiasis.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Fosmanogepix

Report Segments
  • Innovator
Drug Name
  • Fosmanogepix
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.